carlisle medical
Refill Requests shipment tracking contact carlisle medical
Knowledge Center
Industrial related news
Louisiana: Carisoprodol (Soma) Placed in Schedule II Classification
Released: 07/23/2014
By: Carl Richie, Pharmacy Manager

Act 397 (SB 618) of 2014 Legislature - effective August 1. 2014. This law places carisoprodol (Soma) products with the exception of the combination product with codeine) in Schedule II of the Louisiana Uniform Controlled Substances Law. These products were previously listed in Schedule IV of the state list of controlled substances, and they are still listed in that
schedule of the federal list of controlled substances. The combination product with codeine is already listed in Schedule III of the state and federal lists of controlled substances and remains in that schedule on both lists. Effective August 1, the distribution, prescribing and dispensing of carisoprodol products (except the codeine combination product) shall adhere to the usual requirements applicable to Schedule II controlled substances.

Prescriptions for carisoprodol products (with the exception of the combination product with
codeine) issued prior to August 1 shall expire 90 days after the date of issue. Effective August 1,
any refills originally authorized and still remaining on such prescriptions shall be automatically voided.

Prescriptions for carisoprodol products (with the exception of the combination product with
codeine) issued on or after August 1 shall comply with the usual limitations applicable to Schedule II products - may be issued in written or electronic form, expires 90 days after the date of issue,and no refills. Multiple partial fills are permitted provided the total quantity dispensed does not exceed the total quantity prescribed and none are dispensed more than 90 days after the prescription was issued.

<<Back
 
Company News
Generic Releases
Industry Related News
Industry Related Links
Newsletter Subscription
Newsletter Login
 
 
 
 
 
© Copyright 2018 Carlisle Medical, Inc.
Twitter Twitter Twitter Twitter
disclaimer site map disclaimer